№ files_lp_4_process_3_111870
File format: docx
Character count: 5848
File size: 1005 KB
This document outlines a research study aimed at identifying the key outcomes to measure in mild cognitive impairment (MCI) research and gathering input from individuals diagnosed with MCI.
Year:
2023
Region / City:
Bristol
Topic:
Mild Cognitive Impairment Research
Document Type:
Research Study
Institution:
University of Bristol
Author(s):
Dr Nick Turner, Professor Liz Coulthard
Target Audience:
Individuals diagnosed with mild cognitive impairment in the last 12 months
Study Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Funding:
National Institute for Health Research
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Mild to Moderate Support Needs Teaching Performance Expectations Comparison Chart Updated April 2021
Year:
2021
Region / City:
California
Topic:
Education
Document Type:
Educational Guidelines
Author:
Unknown
Target Audience:
Teacher Candidates, Education Specialists
Period of Validity:
Ongoing
Approval Date:
April 2021
Date of Modifications:
N/A
Note:
Year
Subject:
Sports injuries, Concussions
Document Type:
Acknowledgement Form
Target Audience:
Athletes, parents, sports organizations
Year:
2026
Region / City:
London Borough of Merton
Subject:
Referral Form for Learning Disability Services
Document Type:
Referral Form
Organization / Institution:
Merton Integrated Learning Disability Team (MILD)
Author:
Not specified
Target Audience:
Professionals referring individuals for support
Period of Action:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2025
Region / City:
Muncie, IN
Topic:
Education, Special Education
Document Type:
Course Syllabus
Institution:
Ball State University
Instructor:
Maria B. Sciuchetti
Target Audience:
Students enrolled in SPCE 686.800
Period of Validity:
Fall 2025
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Region / City:
Muncie, IN
Topic:
Education, Special Education, Teacher Training
Document Type:
Course Syllabus
Institution:
Ball State University
Instructor:
Dr. Brittany Bales
Target Audience:
Students in Teacher Education Program
Prerequisites:
SPCE 375 with a grade of C or better; overall GPA of 3.0 or better
Course Period:
Fall 2025
Approval Date:
Not specified
Changes Date:
Not specified
Description:
A course syllabus outlining a practicum for students pursuing teaching certification for students with mild disabilities, with field experience and related assessments.
Year:
2021
Region / City:
Alwarkurichi, Tamil Nadu, India
Field:
Corrosion Science
Document Type:
Research Article
Institution:
Sri Paramakalyani College, Alwarkurichi, Tamil Nadu
Author(s):
I. Malar Vizhi, Dr. S. Selvaraj, Dr. K. Kalirajan
Target Audience:
Researchers in corrosion science and materials engineering
Effective Date:
2021
Modification Date:
None
Document Type:
Template letter
Purpose:
Appeal of prior authorization denial
Product Name:
OPZELURA (ruxolitinib) cream 1.5%
Indication:
Mild to Moderate Atopic Dermatitis
Intended Author:
Prescriber
Intended Recipient:
Health Plan or Payer
Target Population:
Non-immunocompromised adult and pediatric patients 12 years of age and older
Subject Matter:
Coverage appeal and prescribing information
Included Sections:
Sample appeal letter, Indication, Limitations of Use, Important Safety Information
Medical Context:
Prior authorization denial and coverage review process
Year:
2023-2024
Region / City:
USA
Subject:
Special Education
Document Type:
Report
Organization / Institution:
ETS
Author:
ETS
Target Audience:
Educators, Policy Makers, Educational Institutions
Effective Period:
2023-2024
Approval Date:
Not specified
Date of Changes:
August 1, 2023
Year:
2024
Region / City:
Australia
Topic:
Psoriasis Treatment
Document Type:
Patient Handout
Organization:
Victorian Government, Department of Health
Author:
Not specified
Target Audience:
Patients with mild plaque psoriasis
Period of validity:
Not specified
Approval Date:
March 2024
Amendment Date:
Not specified
Cost Information:
Free consultation; medicine costs vary based on Medicare and PBS status
Eligibility:
Adults aged 18 or older with mild plaque psoriasis
Additional Support:
Websites provided for more information
Complaint Process:
Information on complaints available at www.health.vic.gov.au/feedback-and-complaints
Safety Net Information:
Medications not included in PBS Safety Net
Consultation Details:
Private consultation with a pharmacist
Prescription Information:
Medicines under PBS or full price for non-listed items
International Students:
Eligible based on specific countries
Consent Process:
Provided during consultation
Health Advice:
Self-care and lifestyle tips included
Expected Outcome:
Symptoms should improve within 2-4 weeks
What to do if symptoms worsen:
Visit a doctor if no improvement or worsening of condition
Contact:
[email protected]
Note:
Year
Context:
A document used to assess the functional capacity of an individual with mild brain impairment for disability support pension purposes.
Year:
2003
Program:
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Type of document:
Supplementary research material
Research field:
Alzheimer’s disease and neurodegenerative disorders
Study type:
Longitudinal neuroimaging and biomarker study
Principal Investigator:
Michael W. Weiner, MD
Participant groups:
Cognitively normal (CN) participants; Mild cognitive impairment (MCI) participants
Participant age range:
55–90 years
Assessment methods:
MRI, PET, biological markers, clinical assessment, neuropsychological testing
Cognitive assessment tools:
Mini-Mental State Exam; Clinical Dementia Rating; Logical Memory II subscale of the Wechsler Memory Scale-Revised
Diagnostic focus:
Mild cognitive impairment and early Alzheimer’s disease progression
Language requirements for participants:
Fluent English or Spanish
Biological sampling:
Blood for genomic analysis and biomarkers; cerebrospinal fluid collection via lumbar puncture
Genomic analysis:
GWAS sequencing and APOE testing
Medication requirements:
Stability of permitted medications and washout from certain psychoactive medications prior to screening
Study participation requirement:
Availability of a study partner with regular participant contact
Imaging requirements:
Repeated MRI (3T) and at least two PET scans
Education requirement:
Minimum six grades of education or adequate work history
Exclusion criteria scope:
Neurologic diseases, psychiatric disorders, substance abuse history, MRI contraindications, unstable medical conditions
Year:
2025
Region / City:
United Kingdom
Topic:
Alzheimer’s Disease, Mild Cognitive Impairment, Dementia Treatment
Document Type:
Appeal
Organization / Institution:
Eli Lilly & Company Ltd
Author:
Eli Lilly & Company Ltd
Target Audience:
Healthcare professionals, Policy makers, Medical researchers
Period of Effectiveness:
Not specified
Approval Date:
23 October 2024
Date of Amendments:
12 June 2025
Topic:
Functional exercise assessment and metabolic equivalent estimation in mild COVID-19
Document type:
Clinical calculation example and methodological note
Medical test:
6-Minute Walk Test
Medical condition:
Coronavirus Disease 2019 (COVID-19)
Clinical parameter:
Metabolic Equivalents (METs)
Measurement units:
feet, meters, meters per minute, miles per hour, ml/kg/min
Example walking distance:
1400 feet in 6 minutes
Converted distance:
427 meters
Calculated walking speed:
71 m/min (2.65 miles/hour)
Estimated oxygen consumption:
10.6 ml/kg/min
Estimated MET level:
approximately 3 METs
Comparative example:
1850 feet in 6 minutes corresponding to approximately 3.7 METs and 94 m/min walking speed
Methodological constants:
1 MET = 3.5 ml/kg/min; conversion constant 0.1 for m/min to ml/kg/min
Field:
Clinical assessment and triage methodology
Year:
2014
Region / City:
Hamilton, Ontario
Theme:
Occupational therapy, Cognitive impairment, Memory clinic
Document type:
Thesis
Organization / Institution:
McMaster University
Author:
Laura Turner
Target Audience:
Healthcare professionals, researchers in cognitive health
Period of validity:
2014 onwards
Approval Date:
May 2014
Date of Changes:
Not specified
Note:
Issue date
Scope:
Children and adults presenting with distress due to pain
Red Flags:
Suspected infection, Recent significant trauma
Indications:
Mild to moderate pain relief, Anti-inflammatory pain relief, Moderate pain relief with codeine
Medicines:
Paracetamol, Ibuprofen, Codeine phosphate
Dosage instructions:
See standing order for age-specific dosing
Route of administration:
Oral
Quantity:
Paracetamol 60 x 500mg tablets or 200mLs suspension, Ibuprofen 40 x 200mg tablets or 200mLs suspension, Codeine 12 x 15mg tablets
Contraindications:
Liver failure, Renal failure, Hypersensitivity to NSAIDs, Severe heart failure, Gastro-intestinal ulceration or bleeding, Acute respiratory depression
Precautions:
Elderly, cardiac impairment, hypertension, risk of sedation, constipation, dependence, drug-seeking behavior
Follow-up:
Return if pain is uncontrolled, worsens, or symptoms change
Countersigning and auditing:
Countersigning required within 48 hours for orders including codeine
Competency/training requirements:
Nurses must be signed off as competent and trained for this standing order
Supporting documentation:
Healthpathways, Best Practice Journal, New Zealand Formulary, Medsafe data sheets, Standing Order Guidelines Ministry of Health 2012, Medicines (Standing Order) Regulations 2012
Signed by issuer:
Name, Title, Date
Year:
2019
Region / city:
OECD
Topic:
Adverse Outcome Pathway, oxidative stress, brain development, neurotoxicity
Document Type:
External Review Report
Author:
OECD EAGMST review manager
Target Audience:
Scientific community, regulators, policymakers
Period of validity:
Not specified
Approval Date:
June 2018
Date of revisions:
17 March 2020
Year:
2026
Region / City:
United States
Topic:
Occupational illness compensation, impairment evaluation
Document type:
Letter, response form
Organization / Institution:
U.S. Department of Labor, Office of Workers’ Compensation Programs
Author:
Unknown
Target audience:
Claimants under EEOICPA
Period of validity:
Indefinite
Approval date:
Not provided
Modification date:
Not provided
Note:
Year
Document Type:
Medical Form
Organization:
World Archery
Target Audience:
Athletes, Medical Professionals
Year:
2022
Region / City:
Kentucky
Topic:
Driver safety, physical or mental impairment
Document Type:
Form
Organization / Institution:
Kentucky Transportation Cabinet, Department of Vehicle Regulation
Author:
Kentucky Transportation Cabinet
Target Audience:
Citizens, law enforcement officers, physicians, judges, government employees
Period of Validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A